National Institutes of Health
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) is a funding opportunity from National Institutes of Health, up to 150000, closing August 11, 2027.
Aug 11, 2027
(376d left)Overview
The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact…